ISRCTN78775328 https://doi.org/10.1186/ISRCTN78775328

Feasibility study using repeated intensive chemotherapy courses for patients with primary acute lymphoblastic leukemia in adults age 18 - 39 years inclusive

Submission date
20/08/2010

Recruitment status
No longer recruiting

Registration date
06/09/2010

Overall study status
Completed

Last Edited
07/09/2011

Condition category
Cancer

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof J.J. Cornelissen

Contact details
Dept. of Hematology
Erasmus MC - Daniel den Hoed
P.O. box 5201
Rotterdam
Netherlands
3008 AE

Additional identifiers

Protocol serial number
Ho70

Study information

Scientific Title

Feasibility study using repeated intensive chemotherapy courses for patients with primary acute lymphoblastic leukemia in adults age 18 - 39 years inclusive: A phase II multicentre study

Acronym
HOVON 70 ALL

Study objectives
The hypothesis to be tested is that treatment with 1 prephase course, 2 induction courses, 1 consolidation course, allo-SCT or maintenance treatment is feasible, and efficacy meets the expectations as described in the protocol.

Ethics approval required
Old ethics approval format

Ethics approval(s)
The Medical Ethics Committee (MEC) of University Medical Centre Groningen approved on the 15th of August 2005 (ref: METc 2005/062)

Study design
Prospective phase II multicentre non-randomised trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Acute Lymphoblastic Leukemia (ALL)

Interventions
Patients will be treated with the following courses:
1. Pre-phase course consisting of 60 mg/m2/day for 7 days. Induction consisting of prednisone, vincristine, daunorubicin, cyclophosphamide and L-asparaginase
2. Consolidation A consisting of 6-thioguanine, cyclophosphamide and Ara-C. Consolidation B consisting of prednisone, vincristine, 6-mercaptopurine and MTX
3. Intensification IA consisting of dexamethasone, vindesine, adriamycine and L-asparaginase
4. Intensification IB consisting of 6-thioguanine, etoposide and Ara-C
5. Interphase A and B consisting of prednisone, vincristing, 6-mercaptopurine and MTX
6. Intensification IIA consisting of prednisone, vincristine, daunorubicine and L-asparaginase
7. Intensification IIB consisting of 6-thioguanine, cyclophosphamide and Ara-C
8. Maintenance consisting of 6-mercaptopurine and MTX

Intervention Type
Other

Phase
Phase II

Primary outcome(s)

Percentage of patients that reach a complete response (CR), complete all intensive phases of the protocol, and start with maintenance therapy within 11 months after start pre-phase or receive an allogeneic stem cell transplantation within 7.5 months after start pre-phase.

Key secondary outcome(s))
1. CR rate after remission induction, consolidation, intensification, and maintenance
2. Toxicity profile related to each treatment step and intervals between treatment steps
3. Event-free survival (i.e. time from registration until no CR on protocol, relapse or death, whichever comes first); Event-free survival for patients without a CR is set at one day
4. Disease-free survival (i.e. time from achievement of CR to day of relapse or death from any cause, whichever occurs first)
5. Overall survival measured from time of registration

Completion date
01/09/2012

Eligibility

Key inclusion criteria
1. Age 18 - 39 years inclusive
2. Primary previously untreated ALL (including Philadelphia chromosome or BCR-ABL positive ALL)
3. WHO performance status 0, 1, or 2
4. Negative pregnancy test at inclusion if applicable
5. Written informed consent

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
All

Key exclusion criteria
1. Mature B-cell ALL
2. Acute undifferentiated leukemia
3. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease)
4. Severe pulmonary dysfunction (CTCAE grade III-IV)
5. Severe neurological or psychiatric disease
6. Significant hepatic dysfunction (serum bilirubin or transaminases ≥ 3 times normal level)

7. Significant renal dysfunction (serum creatinine ≥ 3 times normal level)
8. History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma
9. Active, uncontrolled infections
10. Patient known to be HIV-positive
11. Patient is a lactating woman
12. Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Date of first enrolment
21/10/2005

Date of final enrolment
01/09/2012

Locations

Countries of recruitment
Belgium

Netherlands

Study participating centre
Dept. of Hematology
Rotterdam
Netherlands
3008 AE

Sponsor information

Organisation
Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)

ROR
https://ror.org/056kpdx27

Funder(s)

Funder type
Research organisation

Funder Name
Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)

Funder Name
Dutch Cancer Fund (KWF) (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes